Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma

PharmacoEconomics

Volumn 15, Issue 3, 1999, Pages 305-311

  Uyl de Groot, Carin A ^a   Ossenkoppele, Gert J ^b   Buijt, Ivanne ^a   Huijgens, Peter C ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GRANULOCYTE; HEALTH CARE COST; HOSPITAL COST; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; COSTS AND COST ANALYSIS; FILGRASTIM; HUMANS; LYMPHOMA, NON-HODGKIN; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 0033003204     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915030-00009     Document Type: Article

References (20)

1. Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 1335-47
2. Longo DL, De Vita VT, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38
3. Verdonck LF, Putten WLJ van, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-51
4. Vose JM, Armitage JO, Bierman PJ, et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 1989; 87: 285-8
5. Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-47
6. De Kreuk AM, Ossenkoppele GJ, Meijer CJLM, et al. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 963-71
7. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-8
8. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on haematopoeitic reconstruction after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 593-8
9. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-19
10. Faucher C, Corroller AG le, Blaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901
11. Richel DJ. Peripheral stem cell transplantation opens the way to new treatment strategies. Eur Cancer Centre Newslett 1994: 55-7
12. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using single apheresis. Blood 1993; 82: 3770-7
13. Dufoir T, Saux MC, Terraza B, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992; 10: 323-9
14. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlym-phocytic leukaemia. N Engl J Med 1989; 321: 807-12
15. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by G-CSF (filgrastim): a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A: 1631-5
16. Pettengell R, Woll PJ, Thatcher N, et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-56
17. Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, et al. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Bone Marrow Transplant 1994; 13: 37-41
18. Ossenkoppele GJ, Schuurhuis GJ, Jonkhoff AR, et al. G-CSF (filgrastim) stimulated whole blood kept unprocessed at 40°C does support BEAM-like regimen in bad risk lymphoma. Bone Marrow Transplant 1996; 18: 427-31
19. Uyl-de Groot CA, Ossenkoppele GJ, van der Riet AAPM, et al. Cost analysis of peripheral blood progenitor cell reinfusion mobilised by G-CSF (filgrastim) following high dose Melphalan as compared with high dose Melphalan therapy in multiple myeloma. Eur J Cancer 1994; 30A: 457-9
20. Farmacotherapeutisch Kompas 1995. Amstelveen: Ziekenfondsraad, 1995